HK Stock Market Move | JUNSHI BIO (01877) rose over 4%, with the net loss attributable to shareholders narrowing by 35.7% year-on-year in the first three quarters. The performance of the Tuyi market sales was impressive.

JUNSHI BIO (01877) rose over 4%, at the time of publication, it rose 3.99% to HK$26.06, with a turnover of HK$59,428,600. On the news front, on October 28th, JUNSHI BIO announced that in the first three quarters of 2025, the operating income was RMB 1.806 billion, an increase of 42.06% year-on-year; the net loss attributable to shareholders of the listed company was RMB 596 million, a decrease of 35.7% year-on-year; with a basic loss per share of RMB 0.60. The announcement stated that the growth in operating income during the period mainly came from the increase in sales revenue of commercialized drugs. Among them, the core product Tirzepatide injection (trade name: To Yi/LOQTORZI, product code: JS001) achieved sales revenue of approximately RMB 1.495 billion in the domestic market, a year-on-year increase of about 40%. At the same time, the company continued to implement the "quality improvement, efficiency enhancement, and return to profit" action plan, strengthen cost control and resource focus, significantly narrowing the loss amount compared to the same period last year. As of the end of the reporting period, the company's total balance of cash and trading financial assets was RMB 3.27 billion, with sufficient fund reserves.